Crossject SA Overview
Pro stress-test →Crossject SA is an emerging specialty pharma company based in France and the U.S. developing ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The company leverages its proprietary needle-free injection technology to address critical gaps in emergency medicine delivery.
Strategic Profile
Pro stress-test →The company's ZENEO® needle-free autoinjector is designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. Other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks. The company benefits from government validation and multiple regulatory pathways.
Competitive Landscape
Pro stress-test →Crossject operates in the emergency medicine auto-injector market with competitors including EpiPen (Mylan/Pfizer) and emerging needle-free competitors. The company differentiates through proprietary gas-propulsion ZENEO® technology enabling medication delivery through clothing and on bare skin without needles. Government backing and clinical validation provide competitive moats.
Industry Context
Crossject SA operates in Specialty Pharmaceuticals - Emergency Medicine/Drug Delivery Devices.
Key facts
Founded: 2001 · Headquarters: Dijon, France · Market cap: €115.3M